Drug intelligence / Profile preview

elasomeran + imelasomeran (Moderna Inc)

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**mRNA-1273.214** is Moderna's bivalent COVID-19 mRNA vaccine, marketed as **Spikevax bivalent Original/Omicron BA.1**. It contains two distinct lipid nanoparticle-formulated messenger RNA active ingredients: elasomeran, encoding the SARS-CoV-2 ancestral Wuhan-Hu-1 spike protein, and imelasomeran, encoding the Omicron BA.1 spike protein. Following intramuscular administration, host cells translate the mRNAs and transiently express spike antigens, eliciting neutralizing antibody and cellular immune responses intended to prevent COVID-19. The product was developed as a booster and was evaluated in Phase 2/3 studies; it received authorizations in multiple jurisdictions. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/spikevax-epar-product-information_en.pdf))

Brand names: Spikevax bivalent Original/Omicron BA.1
Other names: Omicron BA.1 bivalent COVID-19 vaccineoriginal/Omicron BA.1 bivalent COVID-19 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on elasomeran + imelasomeran (Moderna Inc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elasomeran + imelasomeran (Moderna Inc).

Explore the full profile